A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors

Conditions

• Solid Tumor Malignancies, Cancer
• CTIT-Chemotherapy Induced Thrombocytopenia
• Thrombocytopenia

Interventions

• DRUG: Human Interleukin-11
• DRUG: Romiplostim N01

Sponsor

Jun wang